Harvard won the visible fight. The quiet one is proving harder to stop.

After the Trump administration froze more than $2.2 billion in federal funding to Harvard last year, the university sued and won. A federal judge forced the administration to reverse the cuts, and Harvard has continued to refuse the kind of settlement other elite universities have weighed. But a New York Times analysis of government data shows that one of Harvard’s most important federal funding streams is still running far below its previous pace. National Institutes of Health funding to the university is about 18% under its average during the Biden administration.

The conflict didn’t end. It changed form. The first version was designed to be seen: announce a freeze, make the fight public, force a political confrontation. The current version is designed not to be. According to the Times, NIH is delaying, reducing or rejecting individual grant requests, leaving researchers and administrators uncertain about what is happening or why. Through June 30 of the current fiscal year, NIH had provided Harvard 309 awards worth $200 million — against an average of roughly 440 awards worth $246 million over the same nine-month window from 2021 through 2024.

The New Tactic Is Administrative

The earlier freeze was easy to challenge precisely because it was sweeping and explicit. Harvard could point to a single act of retaliation and argue the government had violated its constitutional rights. Last September, a judge found the administration had improperly cut off Harvard’s grants and violated the university’s First Amendment rights. The same ruling noted that lawful routes remained available if the government wanted to restrict funding through proper channels.

That is the shift. Not every conflict has to be staged as a headline. Uncertainty can be manufactured inside the machinery that awards, renews and administers grants. A delayed award, a trimmed grant, a rejected application — each can be devastating to a lab and nearly impossible to frame as a discrete unlawful act. The power moved from the press conference to the queue.

For Harvard, that means legal victories don’t restore operational stability. A university can win the case and still lose its planning environment. Nobody builds a lab, hires staff, recruits doctoral students or launches a multiyear project on a symbolic win. They need money that arrives when it’s supposed to.

The Cost Is Not Evenly Distributed

Harvard’s size obscures the damage. It holds one of the largest endowments in higher education and remains among the biggest recipients of NIH funding, which lets critics argue it can absorb the pressure. But federal research money is not a general-purpose allowance. It funds specific labs, projects, staff, students, equipment and pipelines — none of which are interchangeable with endowment returns.

The slowdown is landing unevenly. Harvard’s T.H. Chan School of Public Health, heavily dependent on NIH support, has seen nearly 25% less grant funding this year than its 2021–2024 average. The Times reported the school received $67 million across 63 awards through June, down from a comparable average of $90 million across more than 100.

This is where the story stops being about Harvard as a brand and starts being about research capacity. The Faculty of Arts and Sciences eliminated 165 staff positions through layoffs and restructuring. The public health school has cut back as well, including reductions in Ph.D. slots. Those cuts don’t only affect current employees. They shrink the next cohort of scientists trained inside the American research system — a loss that shows up years from now, in work that never gets done.

Uncertainty Becomes Policy

The administration says the pressure is tied to Harvard’s alleged failures on civil rights, antisemitism and race-conscious practices. A White House spokeswoman told the Times the administration will keep using available legal avenues to enforce civil rights laws unless Harvard comes to the table.

Whatever the stated rationale, the operational effect runs wider. Federal grants are not only payments. They are policy instruments that determine which questions get studied, which labs survive, which young scientists get trained and which universities stay globally competitive. When grantmaking becomes politically unstable, the instability itself becomes a form of governance.

That is why this matters beyond Harvard. The administration has pursued broader changes to federal grant rules that would give political appointees more authority over funding decisions. Scientists and public-health researchers have warned those changes could expose research funding to ideological screening rather than scientific merit.

The State Can Punish Without Announcing Punishment

The deeper lesson is about what government power does after it loses the loud version of a fight.

A public freeze creates a target. A grant slowdown creates fog. Fog pushes universities into defensive budgeting, cautious hiring and narrower research bets. It makes administrators cut before they know the full extent of the damage. It makes scientists wonder whether a proposal was judged on merit, on politics, or on the name of the institution at the top of the page.

That fog is expensive. It produces no courtroom drama, and it still changes behavior. Universities retrench. Labs pause. Students choose other paths. Researchers weigh leaving the country. A system under sustained uncertainty adapts by getting smaller and more cautious — which may be the point.

Harvard’s court wins still matter. They establish that federal power has limits. But the NIH numbers establish something else: winning the case does not end the pressure.

The fight over Harvard’s funding is no longer about whether the government can cut money in public. It is about whether it can make federal support unreliable enough that the university changes anyway.